Novo Nordisk has said that it will boost manufacturing capacity for future obesity drug launches and worry less about marketing and advertising after a bungled market introduction of its Wegovy injection last year.
“As we look to launch future products, obviously, we will take into consideration more of a ‘pull’ than a ‘push’ commercial strategy. And that links into how we scale capacity for that,” Lars Fruergaard Jorgensen, Chief Executive, Novo Nordisk, told journalists in a call on nine-month results.
“We see this pull nature in the market for anti-obesity medicine, which is fantastic because we have the broadest portfolio in the industry to do that,” he added.
The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year.
Edits by EP News Bureau